Financials in USD. Standardized financial statements.
A compact view of how Poseida Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $64.70M | $130.36M | $31,238 | $0 | $0 | $0 | $2.98M | $9.77M |
| Revenue Growth? | -50.4% | +417217.1% | 0.0% | 0.0% | 0.0% | -100.0% | -69.4% | 0.0% |
| Cost of Revenue? | $156.77M | $5.17M | $4.55M | $2.59M | $1.19M | $689,000 | $0 | $0 |
| Gross Profit? | -$92.07M | $125.19M | -$4.52M | -$2.59M | -$1.19M | -$689,000 | $2.98M | $9.77M |
| Gross Margin? | -142.3% | +96.0% | -14472.0% | 0.0% | 0.0% | 0.0% | +100.0% | +100.0% |
| Operating Expenses? | $194.21M | $190.44M | $172,649 | $126,549 | $78.85M | $40.56M | $24.58M | $15.00M |
| Operating Income? | -$129.50M | -$59.95M | -$141,411 | -$126,549 | -$85.53M | -$41.99M | -$19.67M | -$5.45M |
| EBITDA? | -$109.04M | -$51.92M | -$117.06M | -$145.48M | -$91.68M | -$45.12M | -$20.88M | -$5.12M |
| Income Before Tax | -$123.32M | -$63.46M | -$124,974 | -$129,775 | -$86.53M | -$44.61M | -$20.19M | -$5.34M |
| Income Tax Expense | $107,000 | $544,000 | -$4.53M | -$2.58M | $0 | -$202,000 | -$527,000 | -$765,000 |
| Net Income? | -$123.43M | -$64.00M | $4.40M | $2.45M | -$92.64M | -$44.40M | -$19.66M | -$4.58M |
| EPS? | $-1.37 | $-0.89 | $0.07 | $0.04 | $-2.33 | $-1.24 | $-0.49 | $-0.08 |
| Diluted EPS? | $-1.37 | $-0.89 | $0.07 | $0.04 | $-2.33 | $-1.24 | $-0.49 | $-0.08 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality